Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 107

Sort by

Sort Order Select

Journal Articles

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy

Armin Ghobadi, Robert Baiocchi, Amer M. Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Xinyuan Duan, Laurence Gamelin, Kris Michael Mahadeo, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Sandrine Roye, Jean-Claude Vedovato, Susan E Prockop

Blood (2024) 144 (Supplement 1): 70.

https://doi.org/10.1182/blood-2024-198159

Published: 2024

Journal Articles

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Blood (2024) 144 (Supplement 1): 924.

https://doi.org/10.1182/blood-2024-201526

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Real-World Interim PET/CT Scan Use during Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Ran Reshef, Constance Lau, Hil Hsu, Brett Doble, Clare Spooner, Anik R Patel, Liana Nikolaenko

Blood (2024) 144 (Supplement 1): 7775.

https://doi.org/10.1182/blood-2024-200288

Published: 2024

Journal Articles

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Blood (2024) 144 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2024-193827

Published: 2024

Journal Articles

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 931.

https://doi.org/10.1182/blood-2024-202017

Published: 2024

Journal Articles

Multi-Omics Immune Profiling of Graft-Versus-Host Disease (GvHD) in Humans

Lingting Shi, Ajna Uzuni, Michael Pressler, David W Harle, Ximi Kevin Wang, Rodney Macedo, Kirubel Belay, Christian A Gordillo, Shami Chakrabarti, Erik Raps, Xumin Shen, Joshua Fuller, Tamjeed Azad, Jessie Huang, Pranik Chainani, José McFaline-Figueroa, Elham Azizi, Ran Reshef

Blood (2024) 144 (Supplement 1): 381.

https://doi.org/10.1182/blood-2024-205418

Published: 2024

Journal Articles

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

Blood (2024) 144 (Supplement 1): 380.

https://doi.org/10.1182/blood-2024-204010

Published: 2024

Journal Articles

PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL)

Usama Gergis, Aaron Martin, Alex Vogel, Jeff Smith, Andreas Klein, Ran Reshef, Rajneesh Nath, Adam J. Olszewski, Alan List, Alex F. Herrera, Michael D. Jain

Blood (2024) 144 (Supplement 1): 7175.

https://doi.org/10.1182/blood-2024-210499

Published: 2024

Journal Articles

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

Juan Esteban Velez-Hernandez, Mateo Mejia Saldarriaga, Caitlin Unkenholz, Christian A Gordillo, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Markus Y Mapara, Ruben Niesvizky, Ran Reshef, Samuel Yamshon, Mark Bustoros

Blood (2024) 144 (Supplement 1): 7160.

https://doi.org/10.1182/blood-2024-209960

Published: 2024

Journal Articles

5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 864.

https://doi.org/10.1182/blood-2024-194627

Published: 2024

Journal Articles

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Yannis K. Valtis, David Nemirovsky, Sean M. Devlin, Gregory W Roloff, Ibrahim Aldoss, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Anjali S. Advani, Marlise R. Luskin, Evan C. Chen, Omer Jamy, Michael R. Grunwald, Ibrahim Muhsen, Noam E. Kopmar, Bhagirathbhai Dholaria, Simone E. Dekker, Jessica T. Leonard, George Yaghmour, Stephanie B. Tsai, Wendy Stock, Jozal Moore, Kristen M. O'Dwyer, Aaron C. Logan, Matthew P Connor, Noelle Frey, Evandro Bezerra, Sumithira Vasu, Kaitlyn C Dykes, Minoo Battiwalla, Chenyu Lin, Matthew Ulrickson, Ran Reshef, Ryan D. Cassaday, Laquisha C. Hill, Catherine J. Lee, Vamsi K. Kota, Jacob Boccucci, Joshua Sasine, Akil Merchant, Vinod Pullarkat, Amelia Langston, Talal Hilal, Rawan Faramand, Melhem M. Solh, Tamer Othman, Timothy E O'Connor, Navneet Majhail, Shabaz Malik, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Muthu V. Kumaran, Marc Schwartz, Veronika Bachanova, Sean I. Tracy, Maria Odstrcil Bobillo, Abdullah Ladha, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Michael Daunov, John Mathews, Paul Shaughnessy, Bijal D Shah, Lori Muffly, Jae H. Park

Blood (2024) 144 (Supplement 1): 4200.

https://doi.org/10.1182/blood-2024-201610

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis

Blood (2024) 144 (Supplement 1): 4911.

https://doi.org/10.1182/blood-2024-205572

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Blood (2024) 144 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2024-200829

Published: 2024

Journal Articles

Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Blood (2024) 144 (Supplement 1): 2088.

https://doi.org/10.1182/blood-2024-194525

Published: 2024

Journal Articles

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Devang Thakkar, Brian T. Hill, Rachel Kositsky, Shari Tian, Leonardo Biral, Veronica Russell, Tushar Dave, Cassandra L. Love, Caroline Roth, Matthew Stuart McKinney, Ahmed Galal, Jadee Neff, Agrima Mian, Ellen Kendall, Sarah L. Ondrejka, Matthew Chiaramonte, Govind Bhagat, Kenneth N. Ofori, Ran Reshef, Alexandra E. Kovach, Tarsheen Sethi, Emily F. Mason, Shakthi Bhaskar, Olalekan O. Oluwole, Chad McCall, Christopher Pallas, Nilanjan Ghosh, Robert Ferdman, George Chen, Francisco Hernandez-Ilizaliturri, Joanna Zurko, Ashley Cunningham, Nirav C Shah, Boyu Hu, Deborah M. Stephens, Monalisa Ghosh, Neil Bailey, Krish Patel, John M. Pagel, Kavya Kannamma Kannan, Eric D. Hsi, Rakhee Vaidya, Andrew Ip, Andre Goy, Swetha Kambhampati, Robert Ohgami, Charalambos Andreadis, Christian A Gordillo, Brianna Just, Jonathon B Cohen, Arielle Baim, Julie Barbello, Erika Cavallone, Veronika Bachanova, Maureen Laschen, Andinet Teferra, Frederique Lorcy, Sylvain Lamure, Guillaume Cartron, Valerie Dardalhon, Kikkeri N Naresh, Magdalena Czader, Anupama Reddy, Elizabeth Thacker, Clayton Parker, Lanie Happ, Sandeep Dave

Blood (2024) 144 (Supplement 1): 3409.

https://doi.org/10.1182/blood-2024-199758

Published: 2024

Journal Articles

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Caitlin Unkenholz, Mateo Mejia Saldarriaga, Esther Ortega, Jorge Monge, Christian A Gordillo, Juan Esteban Velez-Hernandez, Divaya Bhutani, Roger Pearse, Rajshekhar Chakraborty, Suzanne Lentzsch, Ran Reshef, Ruben Niesvizky, Mark Bustoros

Blood (2024) 144 (Supplement 1): 1936.

https://doi.org/10.1182/blood-2024-210365

Published: 2024

Journal Articles

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Ibrahim Muhsen, Anjali S. Advani, Gregory W Roloff, Nikeshan Jeyakumar, Katharine Miller, Amy Zhang, Katherine C. Sutherland, Michael R. Grunwald, Vamsi K. Kota, Jacob Boccucci, Matthew Ulrickson, Joshua Sasine, Ibrahim Aldoss, Tamer Othman, Sumithira Vasu, Ran Reshef, Marlise R. Luskin, Evan C. Chen, Chenyu Lin, Amelia Langston, Ryan D. Cassaday, Noam E. Kopmar, Stephanie B. Tsai, Timothy E O'Connor, Talal Hilal, Rawan Faramand, Jae H. Park, Yannis K. Valtis, Melhem M. Solh, Evandro Bezerra, Jessica T. Leonard, Simone E. Dekker, Navneet Majhail, Minoo Battiwalla, Shahbaz A. Malik, John Mathews, Paul Shaughnessy, Luke Mountjoy, Rasmus T. Hoeg, Caspian H. Oliai, Vishal Gupta, Divya Koura, Kaitlyn C Dykes, Aaron C. Logan, Muthu V. Kumaran, Wendy Stock, Marc Schwartz, Veronika Bachanova, Sean Tracy, Kristen M. O'Dwyer, Jozal Moore, Catherine J. Lee, Maria Silvina Odstrcil Bobillo, Noelle Frey, Matthew P Connor, Omer Jamy, Michael Daunov, Abdullah Ladha, George Yaghmour, Clayton Jackson, Vivian Irrizary Gatell, Olalekan O. Oluwole, Bhagirathbhai Dholaria, Vinod Pullarkat, Akil Merchant, Bijal D Shah, Lori Muffly, LaQuisa Hill

Blood (2024) 144 (Supplement 1): 523.

https://doi.org/10.1182/blood-2024-210682

Published: 2024

NARROW

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy

TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Real-World Interim PET/CT Scan Use during Frontline (1L) Therapy and Subsequent Treatment Characteristics in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis

Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

Multi-Omics Immune Profiling of Graft-Versus-Host Disease (GvHD) in Humans

Serial Clinical and Biomarker Monitoring during Treatment Can Stratify Patients with Low Risk Gvhd

PBCAR19B, an Immune Evading Allogeneic CAR T Stealth Cell, Demonstrates Potent Anti-Tumor Responses and Prolonged B Cell Depletion Supporting Sustained Immune Evasion in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL)

Absolute Lymphocyte Count after CAR-T Therapy Has Different Kinetics and Predicts Better Outcomes in B-Cell Malignancies

5-Year Follow-up Analysis from ZUMA-5: A Phase 2 Trial of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free Survival

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Long Term Outcomes of a Randomized Trial of Anti-T Lymphocyte Globulin to Improve Moderate-Severe Chronic Gvhd Free Survival after Unrelated Donor Hematopoietic Cell Transplantation: A CIBMTR Analysis

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL

Abnormal Serum Fixation Patterns Are a Common Event Following BCMA CAR-T Therapy in Relapsed Refractory Multiple Myeloma and Are Often Preceded By Immunological Events

Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and Above

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only